Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Hunsaker

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
Plos One|October 6, 2017
Combined MEK and ERK inhibition overcomes therapy-mediated pathway reactivation in RAS mutant tumorsMark Merchant, John Moffat, Gabriele Schaefer, et al.
Bioorganic & Medicinal Chemistry Letters|May 1, 2013
Identification of substituted 2-thio-6-oxo-1,6-dihydropyrimidines as inhibitors of human lactate dehydrogenasePeter S Dragovich, Benjamin P Fauber, Laura B Corson, et al.
Analytical Chemistry|March 6, 2023
Quantifying KRAS G12C Covalent Drug Inhibitor Activity in Mouse Tumors Using Mass SpectrometryJohn C Tran, Thomas Hunsaker, Christina Bell, et al.
Journal of Medicinal Chemistry|July 18, 2008
A pentacyclic aurora kinase inhibitor (AKI-001) with high in vivo potency and oral bioavailabilityThomas E Rawson, Matthias Rüth, Elizabeth Blackwood, et al.
Journal of Medicinal Chemistry|May 27, 2016
Discovery of (S)-1-(1-(4-Chloro-3-fluorophenyl)-2-hydroxyethyl)-4-(2-((1-methyl-1H-pyrazol-5-yl)amino)pyrimidin-4-yl)pyridin-2(1H)-one (GDC-0994), an Extracellular Signal-Regulated Kinase 1/2 (ERK1/2) Inhibitor in Early Clinical DevelopmentJames F Blake, Michael Burkard, Jocelyn Chan, et al.
Bioorganic & Medicinal Chemistry Letters|July 20, 2014
Identification of substituted 3-hydroxy-2-mercaptocyclohex-2-enones as potent inhibitors of human lactate dehydrogenasePeter S Dragovich, Benjamin P Fauber, Jason Boggs, et al.
Journal of Medicinal Chemistry|March 2, 2026
Discovery and Optimization of a Potent, Efficacious, and Brain-Penetrant Inhibitor of KRAS G12CMatthew L Landry, Sushant Malhotra, Maureen Beresini, et al.
Nature|May 6, 2021
ARAF mutations confer resistance to the RAF inhibitor belvarafenib in melanomaIvana Yen, Frances Shanahan, Jeeyun Lee, et al.
Journal of Medicinal Chemistry|March 2, 2026
Discovery and Characterization of Divarasib (GDC-6036), a Potent Covalent Inhibitor of KRAS G12CNicholas F Endres, Steven Do, Rana Mroue, et al.
Nature Communications|June 27, 2026
Covalent pan-TEAD inhibitors block YAP activity and demonstrate brain penetrance in a Hippo-dependent cancer modelThijs J Hagenbeek, Jason Zbieg, Russell Smith, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Plos One|October 6, 2017
Combined MEK and ERK inhibition overcomes therapy-mediated pathway reactivation in RAS mutant tumorsMark Merchant, John Moffat, Gabriele Schaefer, et al.
Bioorganic & Medicinal Chemistry Letters|May 1, 2013
Identification of substituted 2-thio-6-oxo-1,6-dihydropyrimidines as inhibitors of human lactate dehydrogenasePeter S Dragovich, Benjamin P Fauber, Laura B Corson, et al.
Analytical Chemistry|March 6, 2023
Quantifying KRAS G12C Covalent Drug Inhibitor Activity in Mouse Tumors Using Mass SpectrometryJohn C Tran, Thomas Hunsaker, Christina Bell, et al.
Journal of Medicinal Chemistry|July 18, 2008
A pentacyclic aurora kinase inhibitor (AKI-001) with high in vivo potency and oral bioavailabilityThomas E Rawson, Matthias Rüth, Elizabeth Blackwood, et al.
Journal of Medicinal Chemistry|May 27, 2016
Discovery of (S)-1-(1-(4-Chloro-3-fluorophenyl)-2-hydroxyethyl)-4-(2-((1-methyl-1H-pyrazol-5-yl)amino)pyrimidin-4-yl)pyridin-2(1H)-one (GDC-0994), an Extracellular Signal-Regulated Kinase 1/2 (ERK1/2) Inhibitor in Early Clinical DevelopmentJames F Blake, Michael Burkard, Jocelyn Chan, et al.
Bioorganic & Medicinal Chemistry Letters|July 20, 2014
Identification of substituted 3-hydroxy-2-mercaptocyclohex-2-enones as potent inhibitors of human lactate dehydrogenasePeter S Dragovich, Benjamin P Fauber, Jason Boggs, et al.
Journal of Medicinal Chemistry|March 2, 2026
Discovery and Optimization of a Potent, Efficacious, and Brain-Penetrant Inhibitor of KRAS G12CMatthew L Landry, Sushant Malhotra, Maureen Beresini, et al.
Nature|May 6, 2021
ARAF mutations confer resistance to the RAF inhibitor belvarafenib in melanomaIvana Yen, Frances Shanahan, Jeeyun Lee, et al.
Journal of Medicinal Chemistry|March 2, 2026
Discovery and Characterization of Divarasib (GDC-6036), a Potent Covalent Inhibitor of KRAS G12CNicholas F Endres, Steven Do, Rana Mroue, et al.
Nature Communications|June 27, 2026
Covalent pan-TEAD inhibitors block YAP activity and demonstrate brain penetrance in a Hippo-dependent cancer modelThijs J Hagenbeek, Jason Zbieg, Russell Smith, et al.
Pageof 2